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Myocardial contrast echocardiography can define in vivo 
the area at risk for necrosis after coronary occlusion. 
However, if this technique is to be used, it cannot be 
intrinsically toxic to the heart or other critical organs. 
To determine the functional and pathologic effects of 
contrast echocardiography, six intracoronary, six intra-
renal and six intracarotid artery injections of 2 to 6 cc 
of a commonly employed contrast agent (agitated Reno-
grafin-saline solution) were performed in five dogs. A 
sixth dog served as a sham to assess any deleterious 
effects of the model preparation. Two-dimensional echo-
cardiographic images and electrocardiograms were re-
corded during intracoronary injections, and heart rate, 
blood pressure, left ventricular end-diastolic pressure 
and rate of rise of left ventricular pressure (dP/dt) were 
continuously monitored. At 24 hours, echocardiographic 
and hemodynamic measurements were repeated, the dogs 
were killed and the heart, brain and kidneys were re-
moved and prepared for light microscopic examination. 
Quantitative analysis of left ventricular wall motion was 
performed on control, peak contrast, post-contrast and 
24 hour studies. 
Previous studies demonstrating the ability of myocardial 
contrast echocardiography to define in vivo the area at risk 
for necrosis after coronary occlusion have established this 
method as a valuable tool in the experimental study of isch-
emia. However, if injections of an echocardiographic con-
trast agent are to be used for this purpose, particularly in 
conjunction with assessments of ventricular function or 
myocardial histology, or both, it is essential that they not 
be intrinsically toxic to the heart. Furthermore, if this tech-
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With each intracoronary injection, there were tran-
sient decreases in blood pressure (p = 0.05 versus con-
trol) and increases in left ventricular end-diastolic pres-
sure (p = 0.04 versus control). These were associated 
with depression of wall motion in contrast-enhanced re-
gions (p = 0.01 versus control) and ST -T segment changes 
on the electrocardiogram. No significant change in heart 
rate or left ventricular dP/dt was noted. All variables 
normalized with the clearance of the contrast effect and 
remained normal to 24 hours. Light microscopic ex-
amination revealed no myocardial or cerebral changes 
attributable to the contrast agent injections. In three 
kidneys there were nonspecific changes consistent with 
an osmotic diuresis. 
It is concluded that repeated injections of echocar-
diographic contrast medium do not appear to cause per-
manent cardiac functional disturbances or light micro-
scopic evidence of cardiac, renal or cerebral injury, despite 
dramatic acute depression of regional myocardial func-
tion at the time of contrast effect. 
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nique is to be employed in experimental or clinical studies, 
it is equally important that it not have significant adverse 
effects on other critical organs. 
Since the initial studies of Tei et al. (1), a number 
of investigators (2-9) have successfully employed hand-
agitated solutions of Renografin (meglumine diatrizoate and 
sodium diatrizoate) and saline solution as a myocardial con-
trast agent. Although transient mild hemodynamic and 
electrocardiographic changes have been described after in-
jections of this agent into the coronary bed (1,3), and it has 
been shown that the injections elicit a reactive hyperemic 
response (3), there is little information concerning associ-
ated disturbances of ventricular wall motion and no infor-
mation concerning the pathologic sequelae of such injections 
on the heart and other organs. The purpose of this study, 
therefore, was to determine the effects of repeated injections 
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of this agent into the coronary, renal and cerebral circula-
tions by applying quantitative echocardiographic methods 
of ventricular wall motion analysis and light microscopic 
examination of the heart, kidneys and brain. 
Methods 
Animal preparation. The study was performed on five 
mongrel dogs with a mean weight of 21 kg (range 19 to 
23). A sixth dog was used as a sham animal to assess any 
deleterious effects of the model, particularly those caused 
by the placement of the intracoronary catheter. The dogs 
were anesthetized with intravenous pentobarbital (30 mg/kg 
body weight), intubated and ventilated with oxygen-sup-
plemented room air. Blood gases were monitored and main-
tained in the physiologic range. 
A left lateral thoracotomy was performed and a pericar-
dial cradle was created to facilitate echocardiographic im-
aging of the heart. A Millar catheter was introduced through 
the left ventricular apex for continuous monitoring of left 
ventricular rate of rise of pressure (dP/dt) and end-diastolic 
pressure. A 22 gauge Teflon cannula was introduced into a 
right ventricular branch of either the left anterior descending 
or left circumflex coronary artery and advanced retrograde 
until its tip lay just within the lumen of the left anterior 
descending or left circumflex artery, respectively. This line 
was flushed with heparinized saline solution and connected 
to a three-way stopcock. A femoral artery catheter was 
placed to monitor the systemic blood pressure and obtain 
blood for blood gas measurements. Limb lead electrocar-
diographic monitoring was established. 
In the five experimental animals, a left flank incision was 
also performed to allow placement of an 18 gauge Teflon 
catheter into the left renal artery, and the left carotid artery 
was cannulated through a cutdown in the left side of the 
Figure 1. Two-dimensional echocardiogram (short-axis view at 
the level of the chordae) after the injection of contrast medium 
into the left circumflex coronary artery. Note the clear demarcation 
between contrast-enhanced and nonenhanced regions. In the ac-
companying schematic the contrast-enhanced area is indicated by 
the stippled area. 
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neck. These catheters were also flushed with heparinized 
saline solution and connected to three-way stopcocks. 
Contrast agent injections. The echocardiographic con-
trast agent employed was an agitated mixture of equal vol-
umes of Renografin-76 (meglumine diatrizoate and sodium 
diatrizoate, 18.5 g/50 cc; ER Squibb and Sons, Inc.) and 
saline solution (1,4). The volume of contrast medium used 
varied according to the site of injection. Two cubic centi-
meters were used for each intracoronary injection and 6 cc 
for each carotid and renal artery injection. Zero to approx-
imately 0.1 cc of air was added to the solution (as necessary 
to achieve an adequate myocardial contrast effect) and it 
was agitated by rapid transfer of the solution from one sy-
ringe to another through a metal three-way stopcock. After 
removal of visually apparent gaseous macrobubbles, the 
solution was then injected by hand into the preplaced in-
traarterial catheters. This mixture contained microbubbles 
ranging in size from 2 to 25 Ilm (mean 11.5 ± 6.6). All 
injections were performed at 10 minute intervals on the basis 
of pilot studies that demonstrated visual clearing of the 
myocardial echocardiographic contrast effect and resolution 
of all hemodynamic and functional disturbances within this 
time period. 
Study protocol. The five study animals received a series 
of six intracoronary, six intrarenal and six intracarotid artery 
injections of the echocardiographic contrast agent. All coro-
nary artery injections were performed under continuous cross-
sectional echocardiographic monitoring. Satisfactory myo-
cardial contrast enhancement was confirmed with all injec-
tions (Fig. I). Similarly, ultrasonic imaging of the injected 
kidney demonstrated contrast enhancement after renal artery 
injections. A six lead electrocardiogram was recorded im-
mediately before and after each injection of contrast agent. 
Heart rate, aortic pressure, left ventricular end-diastolic 
pressure and left ventricular dP/dt were monitored contin-
uously. In the sham animal, echocardiographic images and 
hemodynamic measurements were recorded immediately and 
3 hours after the placement of the catheters. 
At the completion of the experiment, or in the case of 
the sham animal, 3 hours after line placement, the catheters 
were removed, the chest, abdominal and neck incisions were 
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closed and the pneumothorax was evacuated, Ampicillin, 
500 mg, was administered as prophylaxis against infection, 
and cumulative doses of approximately 20 mg of meperidine 
hydrochloride (Demerol) were given for pain, 
After recovery from the anesthesia, the dogs were ob-
served for gross evidence of neurologic deficit. Twenty-four 
hours later, they were reanesthetized, the chest was re-
opened and cross-sectional imaging, electrocardiographic 
recording and hemodynamic assessments were repeated, The 
dogs were then killed with anesthetic overdose, The heart, 
and in the case of the five experimentai animals, the brain 
and both kidneys were immediately removed and formalin-
fixed. The time of death (24 hours) was selected as one at 
which any damage related to the contrast injection would 
be expected to be apparent on light microscopic examination. 
Two-dimensional echocardiography: data acquisition 
and analysis. Two-dimensional echocardiographic imag-
ing was performed with an A TL Mark III mechanical sector 
scanner using a 5 MHz transducer (Advanced Technologies 
Laboratories). Images were recorded for subsequent anal ysis 
on 1/2 inch (2.54 cm) videotape using a Panasonic NV 8200 
recorder. A saline solution-filled sheet of polyethylene sus-
pended over the heart provided an acoustic interface between 
the echocardiographic transducer and the beating heart. For 
purposes of delineation of the extent of contrast enhance-
ment, echocardiographic images were recorded using short-
axis views of the left ventricle at five levels identified by 
internal landmarks: level of the mitral valve, level of the 
tips of the papillary muscles, midpapillary muscle level, 
basal papillary muscle level and apex. 
Definition of region of contrast enhancement. To map 
the extent of the positive contrast effect, the study tapes 
were reviewed to identify segments from each imaging plane 
in which optimal contrast enhancement was evident. Se-
lected segments were transferred to a Sony -10 10 videodisc 
incorporated into a Microsonics Easy View II off-line anal-
ysis system (Microsonics Inc.). End-diastolic fields were 
identified as those demonstrating the largest endocardial area, 
and the endocardial circumferential extent of the visually 
apparent myocardial contrast effect was measured. In gen-
eral, the contrast effect was relatively homogeneous trans-
murally. In cases in which the margin of the contrast effect 
was slightly irregular, the extent of the contrast effect seen 
in the subendocardial region was used. These values were 
normalized by dividing the length of the segment showing 
contrast enhancement by the entire endocardial circumfer-
ence in the same plane. To facilitate comparison with the 
quantitative wall motion data, the position of the area of 
positive contrast effect was designated using a radial ref-
erence system in which the midpoint of the papillary muscles 
or, in the case of the mitral valve plane, the point on the 
posterior wall midway between the mitral commissures de-
fined the zero reference. To provide a reference for patho-
logic sectioning of the heart, outlines of the echocardio-
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graphic sections and the regions of contrast enhancement 
were also traced onto paper. 
Echocardiographic wall motion analysis. Quantitative 
wall motion analysis was carried out using the midpapillary 
short-axis view. This view was selected, in part, because 
more basal imaging planes did not demonstrate contrast 
enhancement in all animals. More apical levels were ex-
cluded because placement of the apical catheter created lo-
calized disturbances of wall motion and caused acoustic 
shadowing that made it difficult to detect end-systolic en-
docardial borders. 
As the initial step in the analysis of the echocardiographic 
images, the videotapes were reviewed to identify segments 
recorded at the following time periods: control (immediately 
before the first injection of the contrast medium), at the time 
of peak contrast effect during the final contrast agent injec-
tion, immediately after the clearance of the contrast effect 
after the final injection and pre-sacrifice (24 hours after all 
contrast agent injections). For the sham dog, control, 3 hour 
and pre-sacrifice segments were analyzed. Cycles in which 
endocardial visualization was optimal were transferred to a 
videodisc system (Sony SVM-IOlO), and serial endocardial 
and epicardial outlines recorded at 16.7 ms intervals (field 
by field) from end-diastole to end-systole were digitized 
using a Microsonics Easy View II off-line analysis system 
interfaced with a VAX 11-780 computer (Digital Equipment 
Corporation). The end-diastolic echocardiographic field was 
selected as the one demonstrating the largest endocardial 
area. This generally corresponded to within one to two fields 
of the peak of the R wave of the QRS complex noted on 
the simultaneously recorded electrocardiogram. Similarly, 
end-systole was defined as the smallest endocardial area, 
which generally corresponded to the end of the T wave. 
Using computer-assisted methods, the endocardial center of 
area was calculated for each field and, where necessary, the 
endocardial outlines were rotated to ensure alignment of the 
zero reference points (designated on each entered field as 
the midpoint between the papillary muscles). The average 
center of area for all digitized fields was calculated and 36 
evenly spaced rays emanating from this centroid were ex-
tended to intersect each of the entered endocardial outlines. 
Motion of endocardial targets along these rays (that is, 
at 10° increments around the circumference of the ventricle) 
was examined using two previously described methods (10). 
The first generates field by field fractional radial change for 
each of the 36 evenly spaced targets. To provide an index 
of mean zonal function for contrast-enhanced and nonen-
hanced regions, values of the end-systolic fractional radial 
change for five adjacent 10° segments lying in the center of 
the region of contrast enhancement were averaged. Simi-
larly, the mean was calculated for five adjacent myocardial 
segments in the middle of the nonenhanced region. 
To define the circumferential extent of abnormal wall 
motion, we employed a second method which compares 
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observed radial wall motion with a normal systolic con-
traction pattern. Rays correlating with normal motion falling 
outside of the 95% confidence limits defined in each ani-
mal's control study are considered abnormal. Using this 
method, the circumferential extent of wall motion abnor-
mality was calculated and expressed as a percent of the total 
circumference of the short-axis slice. 
Pathology. After formalin fixation, the heart was cut 
into transverse sections that corresponded to the echocar-
diographic imaging planes. Using the traced outlines of the 
contrast-enhanced images as a framework, transmural wedges 
were cut from areas that lay well within both contrast-
enhanced and nonenhanced segments of each slice. For the 
sham heart, wedges were taken from the anterior and pos-
terior walls of each slice. Similarly, representative sections 
of each kidney and coronal sections of right and left cerebral 
hemispheres at the level of the middle cerebral artery were 
taken. 
All pathologic sections were stained with hematoxylin-
eosin and were reviewed without knowledge of their origin 
relative to the distribution of the contrast effect (heart) or 
the site of contrast injection (brain and kidneys). 
Statistical analysis. Comparison across time periods for 
each of the measured variables was performed by repeat 
measures multivariate analysis of variance BMOP4V (BMOP 
Statistical Systems) (11). Comparison between the circum-
ferential extent of abnormal wall motion and the circum-
ferential extent of the contrast effect was carried out by 
paired t testing. All values are reported as mean ± I SO. 
Results 
Timing of contrast effect. As assessed visually, the 
peak contrast effect occurred within 5 to 10 seconds of each 
injection. The contrast enhancement cleared gradually and 
by 40 to 90 seconds none remained. Thus, the immediate 
post-contrast values for the hemodynamic and functional 
variables measured in this study were all taken within 2 
minutes of the contrast injection. 
Hemodynamics. Mean heart rate immediately before each 
intracoronary contrast injection was 128 ± 20 beats/min. 
With each intracoronary injection of contrast agent, there 
was a decrease to 127 ± 22 beats/min (p = NS versus 
control). Similarly, values obtained immediately postcon-
trast clearance and 10 minutes after contrast agent injection 
(128 ± 21 and 127 ± 21 beats/min, respectively) were not 
significantly different from control (Fig. 2A). 
Mean blood pressure at rest was 113 ± 11 mm Hg. With 
each intracoronary contrast medium injection there was a 
transient decrease with mean peak contrast values of 106 
± 8 mm Hg (p = 0.05 versus control). These normalized 
within 10 to 30 seconds. Values noted immediately after 
myocardial contrast clearance and 10 minutes after each 
injection were 112 ± 11 and 113 ± 10 mm Hg (p = NS 
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Figure 2. Changes over time in heart rate (HR) (A), blood pres-
sure (BP) (B), left ventricular (LV) dP/dt (C) and left ventricular 
end-diastolic pressure (LVEOP) (D) after contrast injections. All 
values have been normalized to the control values and are ex-
pressed as mean ± I SO. IMM. POST CC = immediately after 
the clearance of contrast medium; 10 min = 10 minutes after 
contrast injection; 24 hr = 24 hours after all contrast injections 
(pre-sacrifice) . 
versus control) (Fig. 2B). In the control period, dP/dt was 
2,752 ± 587 mm Hg/s. At the time of peak contrast effect, 
there was a slight decrease to 2,504 ± 612 mm Hg/s (p = 
NS versus control). Ten minutes after injection, dP/dt was 
2,774 ± 592 mm Hg/s (p = NS versus control) (Fig. 2C). 
The left ventricular end-diastolic pressure in the control 
period measured 4.6 ± 1.6 mm Hg. This increased briefly 
with each injection of contrast agent to a mean of 6.5 ± 
2.0 mm Hg (p = 0.04 versus control) and decreased to 
normal levels by the time of contrast clearance (4.7 ± 1. 7 
control) (Fig. 20). No significant hemodynamic distur-
bances occurred with either intrarenal or intracarotid con-
trast agent injections. 
Twenty-four hours later, mean heart rate, blood pressure, 
left ventricular end-diastolic pressure and dP/dt were not 
significantly different from control values (128 ± 24 
beats/min, 111 ± 10 mm Hg, 3.5 ± 2.4 mm Hg and 2,820 
± 690 mm Hg/s, respectively). The values for the sham 
dog were similar to the control values for the experimental 
dogs at all sampling periods. 
Electrocardiography. At the time of the peak contrast 
effect nonspecific ST-T segment changes were noted. These 
resolved within 10 minutes. No ectopic beats were present. 
lACC Vol. 6, No.3 
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Wall motion. In the control period, there was no sig-
nificant difference in mean fractional radial change between 
the contrast -enhanced and nonenhanced regions (47.8 ± 
16.2 versus 46.8 ± 10.6%, respectively). 
With intracoronary injections of echocardiographic con-
trast medium, mean fractional change in regions of contrast 
enhancement decreased to 8.6 ± 11.5% at the time of peak 
contrast effect (p < 0.01 versus control). Thus, there were 
regional wall motion abnormalities in the region of contrast 
enhancement. By the time of contrast clearance and at 24 
hours (pre-sacrifice), values were not significantly different 
from control (46.6 ± 12.1 and 41.5 ± 11.3%, respec-
tively). Motion within nonenhanced zones showed no 
significant change with contrast injections (38.4 ± 14.1, 
48.3 ± 19.7 and 41.5 ± 10% at peak contrast, post-contrast 
clearance and pre-sacrifice sampling periods, respectively) 
(Fig. 3). 
The circumferential extent of the contrast-induced ab-
normal wall motion was similar to the circumferential extent 
of contrast enhancement (mean 48.0 ± 3.2 versus 48.6 ± 
4.9%, respectively; p = NS). 
Neurologic function. After the animals had recovered 
from anesthesia, there was no gross evidence of neurologic 
impairment. 
Pathology (Table 1). Heart. No pathologic changes at-
tributable to the injection of echocardiographic contrast were 
noted. In one dog, a nonenhanced segment taken at the mid-
ventricular level showed two subepicardial foci of necrosis. 
In another dog, there was a single focus of round cell in-
filtration in one contrast-enhanced segment. In another dog, 
both contrast-enhanced and nonenhanced segments showed 
Figure 3. Fractional radial change within contrast-enhanced and 
nonenhanced regions at the following sampling periods: control, 
peak contrast, immediately after the clearance of contrast from the 
final injection (lMM. POST CC) and pre-sacrifice (24 hr). Values 
are expressed as mean ± I SD. 
70 
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Table 1. Pathologic Results* 
Heart 
Subepicardial foci of necrosis 
Focus round cell infiltration 
Rare myocytes with contraction 
bands 
Apical areas of infarction ± 
thrombus along path of 
apically placed monitoring 
catheter 
Kidneys 
Cytoplasmic clearing in distal 
tubules 
Brains 
Preterminal petechiae 
Hypertrophied astrocytes (remote 
injury) 
Endothelial proliferation and 
perivascular infiltration of cells 
in caudate nucleus (? hemato-
proliferative disorder, ? 
infectious process) 
With 
Contrast 
Injection 
2 
2 
Without 
Contrast 
Injection 
2 (in I heart) 
3 (+ sham) 
*No pathologic changes attributable to the injection of echocardio-
graphic contrast material were noted. 
rare focal areas of myocytes with contraction bands but 
without evidence of acute infarction. The one consistent 
abnormality in the hearts, including that of the sham dog, 
was evidence of acute subendocardial infarction with or 
without adjacent mural thrombus in both contrast-enhanced 
and nonenhanced regions of the apical segments. This was 
attributed to the apically placed monitoring catheter. No 
abnormalities were noted in the nonapical segments of the 
heart in the sham dog. 
Kidneys. Examination of the kidneys revealed peri-
nuclear cytoplasmic clearing in the distal tubules of two of 
six kidneys with contrast injection and one of six kidneys 
without contrast injection. These changes are nonspecific 
but may be consistent with an osmotic diuresis. 
Brain. Examination of the brain also revealed no patho-
logic changes attributable to the injection of contrast me-
dium. In one brain there were a few fresh petechiae believed 
to be preterminal. In a second brain both hemispheres dem-
onstrated hypertrophied astrocytes which were consistent 
with a response to remote injury. In a third there were 
endothelial proliferation and perivascular infiltration of cells 
in the caudate nucleus which suggested either a hemato-
proliferative disorder or an infectious process. There was 
no evidence of ischemic damage. 
Discussion 
A number of authors (1-9) have successfully used hand-
agitated solutions of Renografin and saline as myocardial 
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echocardiographic contrast agents. By injecting this material 
into the coronary artery tree, it has been possible to define 
accurately the myocardial area at risk from ischemic injury 
after coronary artery occlusion. Its use for this purpose has 
been validated against independent postmortem methods of 
assessing myocardial perfusion (5) as well as histochemical 
(6) and technetium autoradiographic (4) measurements of 
post-coronary occlusion ischemic damage. The technique 
has thus rapidly become established as a valuable experi-
mental tool. 
Adverse effects of Renografin-saline solution when used 
as an echocardiographic contrast agent. The acute hemo-
dynamic and electrocardiographic side effects of such in-
jection have been reported as mild and transient (1,3), and 
in the one study (1) that examined wall motion post-contrast 
injection, no significant change in global fractional area 
change was noted. However, there has been no quantitative 
study of wall motion within contrast-enhanced segments and 
there are no data concerning long-term functional or patho-
logic sequelae in the heart or other vital organs. 
In this study, we noted that selective intracoronary in-
jection of hand-agitated Renografin-saline solution consist-
ently caused transient depression of regional wall motion 
within contrast-enhanced segments. The circumferential ex-
tent of this abnormal wall motion corresponded closely to 
the region of contrast enhancement. The function of non-
enhanced segments was unaltered. Associated with the ab-
normalities of regional wall motion were hemodynamic evi-
dence of transiently impaired ventricular function and non-
specific electrocardiographic abnormalities. It is important, 
however, that these adverse effects were all short-lived and 
at 24 hours there was no pathologic evidence of contrast 
agent-related damage to the heart, brain or kidneys. 
Our findings of contrast-induced reductions in left ven-
tricular dP/dt and systemic blood pressure and increases in 
left ventricular end-diastolic pressure are consistent with the 
findings included in the original description of the use of 
this agent by Tei et al. (I). However, our findings of acute 
depression of wall motion within the contrast-enhanced re-
gion initially appear to be at variance with their report that 
contrast injection elicited no significant change in total frac-
tional area change (1). It is possible, however, that because 
their study considered only total fractional area change, 
depression in contrast-enhanced regions may have been 
missed. This would be particularly likely to have occurred 
if the contrast-enhanced region constituted a relatively small 
proportion of the echocardiographic imaging' 'slice." Cer-
tainly the hemodynamic abnormalities included in the report 
by Tei et al. are consistent with some disturbance of left 
ventricular wall motion. 
There are several potential mechanisms for the functional 
abnormalities observed in this study. These include the di-
rect adverse effect of the contrast "carrier" (in this case, 
Renografin), as well as transient myocardial ischemia due 
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to either replacement of blood by a substance lacking oxygen 
or impedance of flow by microbubbles that block the coro-
nary microvasculature. 
Adverse effects of Renografin alone. The effects of 
Renografin and chemically similar agents that are widely 
used as clinical angiographic contrast agents have been well 
documented (12). The injection of these agents into the 
coronary artery tree elicits metabolic and electrocardio-
graphic alterations (including heart rhythm and rate), as well 
as disturbances of myocardial contractility, coronary blood 
flow and systemic and cardiac pressures. Sinus bradycardia 
and nonspecific electrocardiographic ST-T segment changes 
are frequent (13-19). It is less common for ventricular ar-
rhythmias and conduction disturbances to occur. Decreases 
in systemic blood pressure (13,19,20) and peripheral vas-
cular resistance and increases in left ventricular end-diastolic 
pressure are common (13). Depression of myocardial con-
tractility lasting 5 to 180 seconds has been demonstrated 
using a variety of methods in both human subjects and 
experimental animals (19,21-23). This direct depressant 
effect appears to be partly related to the hyperosmolality of 
standard contrast agents as well as their ionic composition. 
These factors are also important determinants of the post-
contrast increase in coronary blood flow that is consistently 
observed (19,20,24-26). Angiographic contrast media are 
also associated with a variety of biochemical changes in-
cluding abnormal lactic acid and free fatty acid uptake, 
altered lactate/pyruvate ratio (24) and depression of intra-
myocardial oxyhemoglobin dissociation (26,27). 
Thus, many of the changes we have noted in this study 
are similar to those previously reported as being elicited by 
the injection of unagitated Renografin alone. We believe, 
however, that the microbubbles contained within the con-
trast agent may also be important factors in producing the 
abnormalities we have demonstrated. This impression is 
supported by preliminary data obtained with a model similar 
to that employed in this study. These data suggest that 
Renografin, saline solution or Fluosol DA (a synthetic 
oxygen-carrying blood replacement) do not cause visually 
detectable wall motion abnormalities when unagitated, 
whereas their agitated counterparts often do (28). 
In this study the hemodynamic, electrocardiographic and 
wall motion abnormalities seen after contrast injection were 
transient. The time course of their resolution appeared to 
parallel that of the disappearance of the myocardial contrast 
effect so that in the majority of cases, all variables had 
returned to baseline within 10 to 40 seconds and in all cases 
had normalized within 10 minutes. This time course is sim-
ilar to that observed in studies of the hemodynamic and 
electrocardiographic effects of intracoronary Renografin 
injections. 
Applications and limitations of the study results. In 
this study, no functional abnormalities were detected 24 
hours after the injections of contrast agent. Of equal or 
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greater importance is the fact that no pathologic abnormal-
ities attributable to these injections were noted at this time. 
The time of sacrifice, 24 hours after the injection of contrast 
agent, was selected as one at which damage related to the 
injections was expected to be apparent on light microscopic 
examination. It may be argued that because of the small 
number of study animals and the sampling methods em-
ployed, particularly of the brain, small foci of contrast-
related injury might have been missed. Furthermore, it is 
possible that abnormalities might have been noted had elec-
tron microscopic examination or biochemical testing been 
performed. We believe, therefore, that additional studies 
including more sophisticated assessment of neurologic and 
renal function may be necessary before these methods are 
applied to humans. We should point out, however, that when 
used in experimental and clinical studies, the injection of 
echocardiographic contrast material for myocardial contrast 
enhancement is restricted to either the coronary arteries or 
the aortic root and generally requires only small amounts 
of contrast material. In such situations, the amount of con-
trast agent reaching the cerebral, renal or other systemic 
arterial beds would be small. In this study, we exposed the 
renal and cerebral circulations to direct injections of large 
volumes of contrast material, greatly exceeding those used 
in experimental myocardial contrast studies. We consider it 
highly significant, therefore, that even such "worst case" 
exposure failed to elicit pathologic evidence of tissue injury. 
Thus, we are confident that this method can be used re-
peatedly in experimental studies in which functional and 
pathologic assessments are also to be employed without fear 
of jeopardizing long-term survival of experimental animals. 
Because there are definite acute deleterious effects, how-
ever, all functional measurements should be delayed from 
2 to 10 minutes after each injection of contrast material. 
Although we employed only one contrast agent in this 
study, the results are not entirely specific to that agent. 
Echocardiographic contrast agents, as a group, consist of a 
variety of carriers in which gaseous microbubbles are sus-
pended. It is generally accepted that the microbubbles are 
responsible for the contrast effect while the carriers provide 
a medium that encourages the persistence of small stable 
bubbles. 
This study suggests that the replacement of blood by a 
nonoxygenated mixture of Renografin and saline solution 
and microbubbles is associated with no long-term pathologic 
or functional sequelae. It can be reasonably assumed, there-
fore, that a similar volume of any contrast agent that contains 
microbubbles of similar size suspended in a nontoxic carrier 
may also be suitable for experimental use. 
The micro bubbles present in the solution used in this 
study were 11.5 ± 6.6 JLm in size. This is similar to the 
range in size (J 6 ± 13 JLm) reported by Feinstein et al. 
(29). It is of interest that recent studies (29) have suggested 
that echocardiographic contrast agents containing smaller 
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and more uniform microbubbles than those contained in 
hand-agitated solutions may be produced by sonication. To 
the extent that the transient abnormalities we have observed 
are due to the large microbubbles, it would be anticipated 
that they would be less pronounced with contrast agents 
prepared by the sonication. To date, however, the solutions 
treated most successfully with this process have been hy-
pertonic solutions of dextran, dextrose and glucose. There-
fore, although these agents are promising, it is important to 
exclude adverse effects caused by their hypertonicity. Fi-
nally, it should be noted that in this study the contrast agent 
was injected into a non stagnant vascular bed. Whether in-
jection of the same material into an occluded vascular bed 
would be equally free from permanent adverse effects is 
unknown. 
Conclusions. We have demonstrated that the intracor-
onary injection of a commonly employed echocardiographic 
myocardial contrast agent, hand-agitated Renografin-saline 
solution, causes transient disturbances of ventricular wall 
motion within contrast-enhanced regions. These are asso-
ciated with hemodynamic and electrocardiographic changes 
similar to those previously reported with injections of Reno-
grafin alone. Similarly, intrarenal and intracerebral arterial 
injections of the same material in doses far in excess of 
those expected to reach the general circulation after intra-
coronary injection also appear to be devoid of major patho-
logic ill effects. We conclude, therefore, that repeated in-
jections of Renografin-saline solution or other contrast agents 
that consist of similar size microbubbles suspended in a 
nontoxic carrier can be used experimentally without causing 
persistent disturbances of myocardial function or light mi-
croscopic evidence of myocardial, renal or cerebral injury. 
We thank Christopher Slater, Diane Wathen and Robert Ferrante for their 
technical assistance and Kathleen Lundgren for help in the preparation of 
the manuscript. 
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